| Literature DB >> 30283339 |
Huiyong Liu1, Honglei Kang1, Chao Song1, Zuowei Lei1, Li Li2, Jianfeng Guo1, Yong Xu1, Hanfeng Guan1, Zhong Fang1, Feng Li1.
Abstract
Low back pain (LBP) is a common worldwide disease that causes an enormous social economic burden. Intervertebral disc degeneration (IDD) is considered as a major cause of LBP. The process of IDD is complicated and involves both inflammation and senescence. The production of pro-inflammatory cytokines, including tumor necrosis factor (TNF)α and interleukin (IL)-1β, is increased in the degenerating intervertebral disc, inducing extracellular matrix degradation. Urolithin A (UA) is a metabolite compound resulting from the degradation of ellagitannins by gut bacteria. UA has been reported to be useful for the treatment of diseases associated with inflammation, senescence, and oxidative damage. Therefore, we hypothesized that UA may be an effective treatment for IDD. This study examined the effects of UA on IDD in vitro and in vivo and explored their underlying mechanisms. Our findings indicated that UA could attenuate cellular senescence induced by hydrogen peroxide in nucleus pulposus cells. UA treatment decreased TNFα-induced matrix metalloproteinase production and the loss of collagen II. At the molecular level, UA considerably blocked the phosphorylation of the extracellular signal-regulated kinase, c-JUN N-terminal kinase, and Akt pathways. In vivo study illustrated that UA treatment could ameliorate IDD in a needle-punctured rat tail model, which was evaluated by X-ray imaging, magnetic resonance imaging, and histological analysis. Thus, the results of our study revealed that UA may be a useful therapeutic agent for the treatment of IDD.Entities:
Keywords: TNFα; intervertebral disc degeneration; nucleus pulposus cells; senescence; urolithin A
Year: 2018 PMID: 30283339 PMCID: PMC6157327 DOI: 10.3389/fphar.2018.01043
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Sequences of primers used in the qPCR.
| Name | Sequence (5′–3′) |
|---|---|
| GAPDH (rat) | Forward GGCACAGTCAAGGCTGAGAATG |
| Reverse GGTGGTGAAGACGCCAGTA | |
| Collagen II (rat) | Forward CGAGGCAGACAGTACCTTGA |
| Reverse TGCTCTCGATCTGGTTGTTC | |
| Aggrecan (rat) | Forward CTTCCCAACTATCCAGCCAT |
| Reverse TCACACCGATAGATCCCAGA | |
| MMP3 (rat) | Forward GCTCATCCTACCCATTGCAT |
| Reverse GCTTCCCTGTCATCTTCAGC | |
| MMP13 (rat) | Forward GTGTGACAGGAGCTAAGGCA |
| Reverse ATGAACATGGAGGAGCATGA |